Higher mycophenolate dose requirements in children undergoing hematopoietic cell transplant (HCT)

Journal of Clinical Pharmacology

Volumn 48, Issue 4, 2008, Pages 485-494

  Jacobson, Pamala ^a,b   Huang, Jaiyin ^a   Rydholm, Nancy ^c   Tran, Myhang ^b   Defor, Todd ^a   Tolar, Jakub ^a   Orchard, Paul J ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c UNIVERSITY OF MINNESOTA MEDICAL CENTER   (United States)

Author keywords

Hematopoietic cell transplantation; Mycophenolate mofetil; Mycophenolic acid; Pediatrics; Pharmacokinetics

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; FLUDARABINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; THYMOCYTE ANTIBODY;

AREA UNDER THE CURVE; ARTICLE; CHILD; DOSE RESPONSE; DRUG ADSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN;

AREA UNDER CURVE; CHILD; CHILD, PRESCHOOL; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFANT; INFUSIONS, INTRAVENOUS; KIDNEY TRANSPLANTATION; MALE; MYCOPHENOLIC ACID;

EID: 40749089610     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270007313326     Document Type: Article

References (34)

1. Grewal SS, Barker JN, Davies SM, Wagner JE Unrelated donor hematopoietic cell transplantation: marrow or umbilical cord blood ? Blood. 2003 ; 101: 4233-4244.
2. Bullingham RE, Nicholls AJ, Kamm BR Clinical pharmacokinetics of mycophenolate mofetil. Clin Pharmacokinet. 1998 ; 34: 429-455.
3. Picard N., Ratanasavanh D., Premaud A., Le Meur Y., Marquet P. Identification of the UDP-glucuronosyltransferase isoforms involved in mycophenolic acid phase II metabolism. Drug Metab Dispos. 2005 ; 33: 139-146.
4. Mojarrabi B., Mackenzie PI The human UDP glucuronosyltransferase, UGT1A10, glucuronidates mycophenolic acid. Biochem Biophys Res Commun. 1997 ; 238: 775-778.
5. van Gelder T., Le Meur Y., Shaw LM, et al. Therapeutic drug monitoring of mycophenolate mofetil in transplantation. Ther Drug Monit. 2006 ; 28: 145-154.
6. Oellerich M., Shipkova M., Schutz E., et al. Pharmacokinetic and metabolic investigations of mycophenolic acid in pediatric patients after renal transplantation: implications for therapeutic drug monitoring. German Study Group on Mycophenolate Mofetil Therapy in Pediatric Renal Transplant Recipients. Ther Drug Monit. 2000 ; 22: 20-26.
7. Weber LT, Shipkova M., Armstrong VW, et al. The pharmacokineticpharmacodynamic relationship for total and free mycophenolic acid in pediatric renal transplant recipients: a report of the German Study Group on Mycophenolate Mofetil Therapy. J Am Soc Nephrol. 2002 ; 13: 759-768.
8. Jacqz-Aigrain E., Khan Shaghaghi E., Baudouin V., et al. Pharmacokinetics and tolerance of mycophenolate mofetil in renal transplant children. Pediatr Nephrol. 2000 ; 14: 95-99.
9. Filler G., Zimmering M., Mai I. Pharmacokinetics of mycophenolate mofetil are influenced by concomitant immunosuppression. Pediatr Nephrol. 2000 ; 14: 100-104.
10. Weber LT, Shipkova M., Lamersdorf T., et al. Pharmacokinetics of mycophenolic acid (MPA) and determinants of MPA free fraction in pediatric and adult renal transplant recipients. German Study Group on Mycophenolate Mofetil Therapy in Pediatric Renal Transplant Recipients. J Am Soc Nephrol. 1998 ; 9: 1511-1520.
11. Bunchman T., Navarro M., Broyer M., et al. The use of mycophenolate mofetil suspension in pediatric renal allograft recipients. Pediatr Nephrol. 2001 ; 16: 978-984.
12. Filler G. Value of therapeutic drug monitoring of MMF therapy in pediatric transplantation. Pediatr Transplant. 2006 ; 10: 707-711.
13. Shaw LM, Holt DW, Oellerich M., Meiser B., van Gelder T. Current issues in therapeutic drug monitoring of mycophenolic acid: report of a roundtable discussion. Ther Drug Monit. 2001 ; 23: 305-315.
14. van Hest RM, Hesselink DA, Vulto AG, Mathot RA, van Gelder T. Individualization of mycophenolate mofetil dose in renal transplant recipients. Expert Opin Pharmacother. 2006 ; 7: 361-376.
15. Giaccone L., McCune JS, Maris MB, et al. Pharmacodynamics of mycophenolate mofetil after nonmyeloablative conditioning and unrelated donor hematopoietic cell transplantation. Blood. 2005 ; 106: 4381-4388.
16. Jacobson P., Rogosheske J., Barker JN, et al. Relationship of mycophenolic acid exposure to clinical outcome after hematopoietic cell transplantation. Clin Pharmacol Ther. 2005 ; 78: 486-500.
17. Schwartz GJ, Haycock GB, Edelmann CM Jr, Spitzer A. A simple estimate of glomerular filtration rate in children derived from body length and plasma creatinine. Pediatrics. 1976 ; 58: 259-263.
18. Jacobson PA, Green KG, Hering BJ Mycophenolate mofetil in islet cell transplant: variable pharmacokinetics but good correlation between total and unbound concentrations. J Clin Pharmacol. 2005 ; 45: 901-909.
19. Filler G. Renal transplantation: literature review 2004-2005. Pediatr Transplant. 2006 ; 10: 418-428.
20. Jacobson P., Green K., Rogosheske J., et al. Highly variable mycophenolate mofetil bioavailability following nonmyeloablative hematopoietic cell transplantation. J Clin Pharmacol. 2007 ; 47: 6-12.
21. van Hest RM, Doorduijn JK, de Winter BC, et al. Pharmacokinetics of mycophenolate mofetil in hematopoietic stem cell transplant recipients. Ther Drug Monit. 2007 ; 29: 353-360.
22. Hale MD, Nicholls AJ, Bullingham RE, et al. The pharmacokineticpharmacodynamic relationship for mycophenolate mofetil in renal transplantation. Clin Pharmacol Ther. 1998 ; 64: 672-683.
23. Weber LT, Schutz E., Lamersdorf T., et al. Therapeutic drug monitoring of total and free mycophenolic acid (MPA) and limited sampling strategy for determination of MPA-AUC in paediatric renal transplant recipients. The German Study Group on Mycophenolate Mofetil (MMF) Therapy. Nephrol Dial Transplant. 1999 ; 14 (suppl 4). 34-35.
24. Osunkwo I., Bessmertny O., Harrison L., et al. A pilot study of tacrolimus and mycophenolate mofetil graft-versus-host disease prophylaxis in childhood and adolescent allogeneic stem cell transplant recipients. Biol Blood Marrow Transplant. 2004 ; 10: 246-258.
25. Militano O., Hedgpeth D., Shaw LM, et al. 315: Pharmacokinetics (PK) of mycophenolate mofetil (MMF) in pediatric allogeneic stem cell transplant (AlloSCT) recipients. Biol Blood Marrow Transplant. 2007 ; 13: 114-115.
26. Filler G., Mai I. Limited sampling strategy for mycophenolic acid area under the curve. Ther Drug Monit. 2000 ; 22: 169-173.
27. Ng J., Rogosheske J., Barker J., Weisdorf D., Jacobson PA A limited sampling model for estimation of total and unbound mycophenolic acid (MPA) area under the curve (AUC) in hematopoietic cell transplantation (HCT). Ther Drug Monit. 2006 ; 28: 394-401.
28. Kaplan B., Gruber SA, Nallamathou R., Katz SM, Shaw LM Decreased protein binding of mycophenolic acid associated with leukopenia in a pancreas transplant recipient with renal failure. Transplantation. 1998 ; 65: 1127-1129.
29. Mudge DW, Atcheson BA, Taylor PJ, Pillans PI, Johnson DW Severe toxicity associated with a markedly elevated mycophenolic acid free fraction in a renal transplant recipient. Ther Drug Monit. 2004 ; 26: 453-455.
30. Basara N., Blau WI, Kiehl MG, et al. Mycophenolate mofetil for the prophylaxis of acute GVHD in HLA-mismatched bone marrow transplant patients. Clin Transplant. 2000 ; 14: 121-126.
31. Bornhauser M., Schuler U., Porksen G., et al. Mycophenolate mofetil and cyclosporine as graft-versus-host disease prophylaxis after allogeneic blood stem cell transplantation. Transplantation. 1999 ; 67: 499-504.
32. Jenke A., Renner U., Richte M., et al. Pharmacokinetics of intravenous mycophenolate mofetil after allogeneic blood stem cell transplantation. Clin Transplant. 2001 ; 15: 176-184.
33. Kiehl MG, Shipkova M., Basara N., et al. Mycophenolate mofetil in stem cell transplant patients in relation to plasma level of active metabolite. Clin Biochem. 2000 ; 33: 203-208.
34. Kuypers DR, Claes K., Evenepoel P., et al. Long-term changes in mycophenolic acid exposure in combination with tacrolimus and corticosteroids are dose dependent and not reflected by trough plasma concentration: a prospective study in 100 de novo renal allograft recipients. J Clin Pharmacol. 2003 ; 43: 866-880.